Literature DB >> 6372095

Reversal of adriamycin resistance by verapamil in human ovarian cancer.

A M Rogan, T C Hamilton, R C Young, R W Klecker, R F Ozols.   

Abstract

The effectiveness of adriamycin in the treatment of ovarian cancer and other human tumors has been limited by the development of drug resistance. Verapamil, a calcium channel blocking agent, completely reversed adriamycin resistance in human ovarian cancer cells with moderate (three- to sixfold) degrees of resistance and partially reversed resistance in highly (150-fold) resistant cells. The potentiating effect of verapamil was due to inhibition of adriamycin efflux in the resistant cells. These results have led to a clinical trial of adriamycin and verapamil in refractory ovarian cancer patients.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6372095     DOI： 10.1126/science.6372095

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  97 in total

Review 1.  Overcoming drug resistance in ovarian carcinoma.

Authors:  P M Fracasso
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

2.  Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay.

Authors:  L M Levasseur; H Faessel; H K Slocum; W R Greco
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

Review 3.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.

Authors:  H Hamada; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

5.  A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.

Authors:  T Langenbuch; K Mross; W Jonat; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry.

Authors:  K Nooter; R Oostrum; R Jonker; H van Dekken; W Stokdijk; G van den Engh
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 7.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

8.  Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro.

Authors:  E M Gibby; O Boyse; B T Hill
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour.

Authors:  W Van de Vrie; E E Gheuens; N M Durante; E A De Bruijn; R L Marquet; A T Van Oosterom; A M Eggermont
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

10.  Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors.

Authors:  F Formelli; L Cleris; R Carsana
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.